Analysis of the Authorized Target Populations for Fixed Dose Combination Products Between 2000 and 2017 Reveals Discrepancies Between EMA’s and FDA’s Views on Initial Dual-Therapy

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Analysis of the Authorized Target Populations for Fixed Dose Combination Products Between 2000 and 2017 Reveals Discrepancies Between EMA’s and FDA’s Views on Initial Dual-Therapy. / Bjerrum, Ole Jannik; Eichendorff, Sascha; Alkis, Nada Bassam.

In: Therapeutic Innovation & Regulatory Science, 2019.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Bjerrum, OJ, Eichendorff, S & Alkis, NB 2019, 'Analysis of the Authorized Target Populations for Fixed Dose Combination Products Between 2000 and 2017 Reveals Discrepancies Between EMA’s and FDA’s Views on Initial Dual-Therapy', Therapeutic Innovation & Regulatory Science. https://doi.org/10.1177/2168479019836976

APA

Bjerrum, O. J., Eichendorff, S., & Alkis, N. B. (2019). Analysis of the Authorized Target Populations for Fixed Dose Combination Products Between 2000 and 2017 Reveals Discrepancies Between EMA’s and FDA’s Views on Initial Dual-Therapy. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1177/2168479019836976

Vancouver

Bjerrum OJ, Eichendorff S, Alkis NB. Analysis of the Authorized Target Populations for Fixed Dose Combination Products Between 2000 and 2017 Reveals Discrepancies Between EMA’s and FDA’s Views on Initial Dual-Therapy. Therapeutic Innovation & Regulatory Science. 2019. https://doi.org/10.1177/2168479019836976

Author

Bjerrum, Ole Jannik ; Eichendorff, Sascha ; Alkis, Nada Bassam. / Analysis of the Authorized Target Populations for Fixed Dose Combination Products Between 2000 and 2017 Reveals Discrepancies Between EMA’s and FDA’s Views on Initial Dual-Therapy. In: Therapeutic Innovation & Regulatory Science. 2019.

Bibtex

@article{fe1828b9157240869f69c50f96b0d07b,
title = "Analysis of the Authorized Target Populations for Fixed Dose Combination Products Between 2000 and 2017 Reveals Discrepancies Between EMA{\textquoteright}s and FDA{\textquoteright}s Views on Initial Dual-Therapy",
author = "Bjerrum, {Ole Jannik} and Sascha Eichendorff and Alkis, {Nada Bassam}",
year = "2019",
doi = "10.1177/2168479019836976",
language = "English",
journal = "Therapeutic Innovation & Regulatory Science",
issn = "2168-4790",
publisher = "SAGE Publications",

}

RIS

TY - JOUR

T1 - Analysis of the Authorized Target Populations for Fixed Dose Combination Products Between 2000 and 2017 Reveals Discrepancies Between EMA’s and FDA’s Views on Initial Dual-Therapy

AU - Bjerrum, Ole Jannik

AU - Eichendorff, Sascha

AU - Alkis, Nada Bassam

PY - 2019

Y1 - 2019

U2 - 10.1177/2168479019836976

DO - 10.1177/2168479019836976

M3 - Journal article

JO - Therapeutic Innovation & Regulatory Science

JF - Therapeutic Innovation & Regulatory Science

SN - 2168-4790

ER -

ID: 246675039